MedTrace Logo

Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome

NCT02513784 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-09-22

Study results available
· View outcomes & findings →

Summary

This is a randomized, open-label pilot study to assess whether treatment with chlorhexidine mouthwash can alter the esophageal and gastric cardia microbiome

Conditions

  • Esophageal Adenocarcinoma
  • Barrett's Esophagus
  • Reflux Esophagitis

Interventions

DRUG

Chlorhexidine gluconate

Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.

Sponsors & Collaborators

Principal Investigators

  • Julian A. Abrams, MD, MS · Assistant Professor of Medicine and Epidemiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02513784 on ClinicalTrials.gov